Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.
Mark Agulnik, MD, a medical oncologist at Keck Medicine of USC, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.
Desmoid tumors are complex conditions with a pattern of growth and regression, necessitating careful monitoring of their longitudinal progression, according to Agulnik. Initial treatment typically does not start unless there's an urgent medical need, focusing instead on evaluating the natural history of the disease.
Treatment is considered if the tumor causes significant pain, impairs function, or negatively impacts the patients’ quality of life. Standard therapy now favors drug treatments over surgical resection due to the high recurrence risk associated with surgery. Agulnik says this shift reflects improved understanding of the disease's behavior, leading to more patient-beneficial systemic therapies.
TRANSCRIPTION:
0:10 | Desmoid tumors are very complex. There's a very unique process to this condition. There is a ‘wax and wane’ type of quality, and so patients can have growth of the tumor, and then they can have subsequent regression of the tumor. So, one needs to be very aware of what's happening. They have to understand the longitudinal process of the disease, and also, they have to understand what are the inherent needs at the time that the patients are seen.
0:37 | If a patient is seen for the first time, there likely is not a need to start treatment unless there is an impending medical emergency, but for the most part, these patients need to be evaluated, and then a longitudinal evaluation needs to be done to understand the natural history of the disease. If the disease or the tumor grows over time or is causing significant problems for the patient with respect to pain, disruption of ability to function [or] their activities of daily living, or affecting quality of life, then it is reasonable to start patients on a therapy. Currently, the standard first-line therapies would be drug therapies for most patients. Many years ago, the standard treatments would have been for surgical resection. But that has changed over time because we have a better understanding that these diseases do come back after surgical resections for many patients, and therefore, if we could take a path to systemic therapy or drug therapy, that is in the patient's best interest.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More